Eralfon 40000 IU 1 ml syringe with needle protection device

Active ingredient

Composition

1 syringe contains 40000 IU of recombinant human erythropoietin

Excipients:

Sodium chloride – 5.84 mg,

sodium citrate pentasquihydrate – 5.8 mg or sodium citrate dihydrate – 4.776 mg,

albumin solution (in terms of dry albumin) – 2.5 mg,

citric acid monohydrate – 0.057 mg,

d/i water – up to 1 ml.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

In the beginning of treatment there may be flu-like symptoms: dizziness, somnolence, feverishness, headache, myalgia, arthralgia.

Systems: dose-dependent increase of BP, worsening of arterial hypertension course (most frequently in patients with chronic renal failure); in single cases – hypertensive crisis, sharp increase of BP with encephalopathy symptoms (headache, mental confusion) and generalized tonic-clonic convulsions.

Hematopoietic organs: thrombocytosis, in some cases – thrombosis of shunt or arteriovenous fistula (including patients on hemodialysis with a tendency to arterial hypotension or with aneurysm, stenosis), aplasia of red blood cell generation.

Allergic reactions: skin rash (mild to moderately expressed), eczema, urticaria, pruritus, angioedema.

Local reactions: hyperemia, burning, mild to moderate soreness at the injection site (more common with pneumonic administration).

Laboratory findings: decreased serum ferritin concentration, in uremia – hyperkalemia, hyperphosphatemia.

Others: complications associated with respiratory distress or with a decrease in BP, immune reactions (induction of antibody formation), exacerbation of porphyria.

Overdose

Similarities